Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors

ABSTRACT The presence of various levels of anti-adenovirus serotype 5 (Ad5)-neutralizing antibodies in humans is thought to contribute to the inconsistent clinical results obtained so far in diverse gene transfer and vaccination studies and might preclude universal dosing with recombinant Ad5. Prescreening of individuals eligible for Ad5 or alternative serotype treatment and subsequently tailoring the vector dose might aid in ensuring the consistency of clinical parameters. For this purpose, a qualified Ad neutralization assay is required. Here we have tested the different protocols used to date to determine anti-Ad neutralizing activity. Based on simplicity, speed, high throughput, sensitivity, and robustness, we propose a qualified assay in which Ad neutralization is monitored by luciferase reporter gene expression.

[1]  D. Klein,et al.  Proviral load determination of different feline immunodeficiency virus isolates using real‐time polymerase chain reaction: Influence of mismatches on quantification , 1999, Electrophoresis.

[2]  Z. Xiang,et al.  Novel, Chimpanzee Serotype 68-Based Adenoviral Vaccine Carrier for Induction of Antibodies to a Transgene Product , 2002, Journal of Virology.

[3]  A. Sanchez,et al.  Development of a preventive vaccine for Ebola virus infection in primates , 2000, Nature.

[4]  N. del Grosso,et al.  Neutralizing antibodies against 33 human adenoviruses in normal children in Rome , 1982, Journal of Hygiene.

[5]  G. Schuler,et al.  Viral vectors for dendritic cell-based immunotherapy. , 2001, Current topics in microbiology and immunology.

[6]  D. Dichek,et al.  Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. , 1997, The Journal of clinical investigation.

[7]  G. Gray,et al.  Simplified Microneutralization Test for Serotyping Adenovirus Isolates , 2001, Journal of Clinical Microbiology.

[8]  V. Mautner,et al.  Neutralisation of adenovirus infectivity by ascitic fluid from ovarian cancer patients , 2000, Gene Therapy.

[9]  S. Kostense,et al.  Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity , 2003, Journal of Virology.

[10]  J Desmyter,et al.  Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. , 1988, Journal of virological methods.

[11]  M. Tsuji,et al.  Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  D. Klein,et al.  Accurate estimation of transduction efficiency necessitates a multiplex real-time PCR , 2000, Gene Therapy.

[13]  A. van der Eb,et al.  New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. , 1998, Human gene therapy.

[14]  P. Opolon,et al.  Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. , 1997, The Journal of clinical investigation.

[15]  Henryk Mach,et al.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity , 2002, Nature.

[16]  D. Schnurr,et al.  Quantitative colorimetric microneutralization assay for characterization of adenoviruses , 1994, Journal of clinical microbiology.

[17]  R. Truitt,et al.  Characterization of human proliferative T cell responses to adenovirus. , 1995, The Journal of infectious diseases.

[18]  S. Kuriyama,et al.  Inhibitory effects of human sera on adenovirus-mediated gene transfer into rat liver. , 1998, Anticancer research.

[19]  B. Ramsey,et al.  Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors. , 1998, Pediatrics.

[20]  L. Leinwand,et al.  Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes , 1996, Journal of virology.

[21]  J. Broderson,et al.  Antigenic relationships among the 47 human adenoviruses determined in reference horse antisera , 2005, Archives of Virology.

[22]  D. Yu,et al.  Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy. , 2000, Human gene therapy.